Small molecule c‐MET inhibitor PHA665752: Effect on cell growth and motility in papillary thyroid carcinoma

c‐Met is upregulated in papillary thyroid carcinoma (PTC) and can be an attractive therapeutic target. We tested the effects of the small molecule c‐met inhibitor PHA665752 in blocking c‐met–dependent phenotypic effects in PTC cell lines.

[1]  T. Nakajima,et al.  c‐Met expression of thyroid tissue with special reference to papillary carcinoma , 1998, Pathology international.

[2]  A. Bardelli,et al.  Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. , 1991, The EMBO journal.

[3]  J. Christensen,et al.  c-Met: Structure, functions and potential for therapeutic inhibition , 2003, Cancer and Metastasis Reviews.

[4]  K. Furge,et al.  Met receptor tyrosine kinase: enhanced signaling through adapter proteins , 2000, Oncogene.

[5]  M. Furihata,et al.  Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. , 1999, Pathology, research and practice.

[6]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Jilin Sun,et al.  Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. , 2006, Cancer research.

[8]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[9]  S. Asa,et al.  Papillary thyroid carcinoma: an overview. , 2009, Archives of pathology & laboratory medicine.

[10]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[11]  G. V. Vande Woude,et al.  Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Christensen,et al.  A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin , 2005, Clinical Cancer Research.

[13]  H. Fujii,et al.  c-Met Expression in Gastric Cancer with Liver Metastasis , 2002, Oncology.

[14]  E Medico,et al.  Met overexpression confers HGF‐dependent invasive phenotype to human thyroid carcinoma cells in vitro , 1999, Journal of cellular physiology.

[15]  A. Costantino,et al.  Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. , 2004, Endocrinology.

[16]  David E Fisher,et al.  Inhibition of the Met Receptor in Mesothelioma , 2005, Clinical Cancer Research.

[17]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.

[18]  G. Navon,et al.  HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells. , 2000, Neoplasia.

[19]  G. Francis,et al.  Over‐expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma , 2000, Clinical endocrinology.

[20]  B. Elliott,et al.  Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. , 1996, The American journal of pathology.

[21]  J. Christensen,et al.  Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. , 2005, Neoplasia.

[22]  R. Salgia,et al.  Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. , 2007, American journal of physiology. Lung cellular and molecular physiology.